A new generation of GLP-1 receptor agonists is showing unprecedented results in treating not just obesity but a cluster of metabolic conditions — including a liver disease that affects nearly one in four adults worldwide. The latest clinical data, presented at the European Congress of Endocrinology in Vienna this week, suggests these drugs may be the most significant advance in metabolic medicine since the discovery of insulin.
The headline finding involves MASHLD — metabolic dysfunction-associated steatotic liver disease, formerly known as NASH. In a Phase 3 trial of 1,850 patients, the next-generation GLP-1/GIP dual agonist achieved liver fibrosis resolution in 63 percent of participants after 72 weeks, compared with 25 percent in the placebo group. The results exceeded analyst expectations and sent the drug’s manufacturer’s stock up 12 percent in after-hours trading.
“We are seeing liver damage reversal at rates we never thought possible with a pharmacological intervention. This is not incremental — this is transformative.” — Dr. Elena Rodriguez, hepatologist, University of Barcelona
The implications extend far beyond liver disease. GLP-1 drugs are now being studied — and in some cases already approved — for conditions including Type 2 diabetes, cardiovascular risk reduction, kidney disease, and sleep apnea. A major trial published in the New England Journal of Medicine last month showed a 20 percent reduction in major cardiovascular events among obese patients without diabetes who took semaglutide, the active ingredient in Wegovy.
The market is responding accordingly. Global GLP-1 drug sales reached $78 billion in 2025, up from $44 billion the previous year, and analysts at Goldman Sachs project the market will exceed $150 billion by 2028. Pfizer, Roche, and AstraZeneca are all racing to develop oral versions that could eliminate the need for injections.
But access remains a critical challenge. In the United States, a month’s supply of Wegovy costs approximately $1,350 without insurance coverage, and many employer health plans still exclude weight-loss drugs. In low- and middle-income countries — where obesity and metabolic disease rates are rising fastest — GLP-1 drugs remain essentially unavailable outside private clinics.
Side effects remain a concern. Gastrointestinal issues — nausea, vomiting, and diarrhea — affect roughly 20 to 30 percent of users, though these typically subside after the first few weeks. More serious concerns include potential links to pancreatitis and thyroid tumors, though the data remains inconclusive. Regulatory agencies in both the US and EU have mandated long-term safety studies.
The science is moving faster than the systems designed to deliver it. The question is no longer whether GLP-1 drugs work — it is whether the world can afford to make them available to everyone who needs them.
Written by Elena Rodriguez, International Affairs Correspondent